The Ever-Changing Hepatitis C Space

Without a doubt, the launch of Gilead Sciences' (NASDAQ: GILD  ) hepatitis C drug Sovaldi has been stellar. While very early, the drug has performed better than Vertex Pharmaceuticals' (NASDAQ: VRTX  ) Incivek, which reached $1 billion in sales in less than a year after it launched in 2011.

The big question is whether Gilead can keep the momentum going. Its all-oral cocktail that includes Sovaldi is under review at the Food and Drug Administration, which should make it more appealing than the current regimen that requires many patients to also inject peginterferon, which has nasty side effects.

Unfortunately Gilead isn't the only company working on an all-oral concoction. AbbVie (NYSE: ABBV  ) is hot on Gilead's tails with its own all-oral cocktail that should be submitted to the FDA in the second quarter.

Gilead and AbbVie will ultimately be battling for an ever-shrinking population of patients, because once a patient is cured, he or she no longer needs the medication. Gilead estimates there could be as many as 4.1 million people in the U.S. infected by hepatitis C, but more than half of them don't even know they're infected.

In the video below, Fool contributor Brian Orelli and health-care bureau chief Max Macaluso discuss the ever-changing dynamics in the hepatitis C space.

Biotech isn't the only sector where investors can find powerhouse growth stocks
The  trick to investing in hyper-growth stocks is to find a small-cap "pure-play" and then watch as it grows in EXPLOSIVE lockstep with its industry. Our expert team of equity analysts has identified one stock that's poised to produce rocket-ship returns with the next $14.4 TRILLION industry. Click here to get the full story in this eye-opening report.

Read/Post Comments (1) | Recommend This Article (0)

Comments from our Foolish Readers

Help us keep this a respectfully Foolish area! This is a place for our readers to discuss, debate, and learn more about the Foolish investing topic you read about above. Help us keep it clean and safe. If you believe a comment is abusive or otherwise violates our Fool's Rules, please report it via the Report this Comment Report this Comment icon found on every comment.

  • Report this Comment On March 08, 2014, at 8:17 PM, badeconomy wrote:

    Abbv hapc is a very weak competition to Sovaldi in every aspect based on the physicians respond to effectiveness of Sovaldi in a short time that has been on the market.

Add your comment.

Sponsored Links

Leaked: Apple's Next Smart Device
(Warning, it may shock you)
The secret is out... experts are predicting 458 million of these types of devices will be sold per year. 1 hyper-growth company stands to rake in maximum profit - and it's NOT Apple. Show me Apple's new smart gizmo!

DocumentId: 2868876, ~/Articles/ArticleHandler.aspx, 8/27/2015 3:30:37 PM

Report This Comment

Use this area to report a comment that you believe is in violation of the community guidelines. Our team will review the entry and take any appropriate action.

Sending report...

Brian Orelli

Dr. Orelli is a Senior Biotech Specialist. He has written about biotech, pharmaceutical, and medical device companies for The Motley Fool since 2007.

Today's Market

updated Moments ago Sponsored by:
DOW 16,387.06 101.55 0.62%
S&P 500 1,961.25 20.74 1.07%
NASD 4,737.58 40.05 0.85%

Create My Watchlist

Go to My Watchlist

You don't seem to be following any stocks yet!

Better investing starts with a watchlist. Now you can create a personalized watchlist and get immediate access to the personalized information you need to make successful investing decisions.

Data delayed up to 5 minutes

Related Tickers

8/27/2015 3:15 PM
ABBV $63.27 Up +0.13 +0.21%
AbbVie Inc. CAPS Rating: ****
GILD $105.91 Down -1.05 -0.98%
Gilead Sciences CAPS Rating: *****
VRTX $131.09 Up +0.98 +0.75%
Vertex Pharmaceuti… CAPS Rating: ****